Evercore ISI analyst Vijay Kumar has maintained their bullish stance on BSX stock, giving a Buy rating on October 20.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vijay Kumar has given his Buy rating due to a combination of factors including Boston Scientific’s robust financial performance and strategic growth initiatives. The company reported a significant 15.3% organic revenue growth in the third quarter, with total revenues reaching $5.1 billion, surpassing expectations by 2%. The cardiovascular segment, in particular, showed impressive growth of 19%, driven by strong performances in electrophysiology and the Watchman device, both exceeding expectations.
Furthermore, Boston Scientific has raised its full-year guidance, anticipating a 15.5% organic growth, and has improved its earnings per share forecast. The company is also making strategic advancements in product development, such as the anticipated launch of Farapoint PFA by the end of 2025 and the expansion of the Watchman device’s market penetration. These factors, combined with a strong operational margin and a positive outlook for future growth, underpin Kumar’s Buy rating for the stock.